

Depressive Disorder: A General Overview

Baitong Ji^{1,a,*}

¹*Department of psychology, auburn university, auburn, USA*

a. Bzj0031@auburn.edu

**corresponding author*

Abstract: Many people have just one side of the story or an incomplete picture when it comes to depression, despite the fact that it is one of the most frequent mental conditions. Many depressive disorders share symptoms, including persistent depressive disorder and major depressive disorder, which both have some of the same effects on people's lives. People who are diagnosed with major depressive disorder have a one in five chance of developing a persistent form of the disease that lasts for two years or more. This percentage is equivalent to around twenty percent of the total population. This article offers a general overview of chronic depression, including topics such as its causes, effects, and treatment options. The etiology of depression are genetic and environmental, and the relevant experiments and theories are described in detail in this article. Genetic factors are mainly congenital overproduction or suppression of neurotransmitters in the brain, while environmental factors are mainly reflected in work. Treatment is mainly based on medication and cognitive therapy. This paper provides a comprehensive understanding of the state of depression. Previous studies have made it difficult to say which has a greater influence on the cause of the disease, the genes or the environment, and the environment mostly refers to the work environment, with very little on the home environment. Experiments on family research should be carried out in the future.

Keywords: Chronic, Depression, Neurotransmitters, Environment, Treatment.

1. Introduction

According to DSM 5, dysthymia is another name for persistent depressive illness, generally known as PDD, present for most days of the two years. Many patients who suffer from persistent depressive disorder also suffer from major depressive disorder (MDD); the combination of these two conditions is referred to as double depression [1]. Major depressive disorder and persistent depressive disorder share so many similarities in terms of symptoms, causes, and treatments that the two depressive disorders are often discussed together. In children and adolescents, persistent depressive must be lasting one year at least, with the annoying mood. Its symptoms are less severe than those of major depressive disorder [2]. In general, cognitive symptoms are more common in PDD, like low self-esteem and unwilling to socialize. It will be difficult to diagnose PDD in psychiatry and primary care settings until the condition deteriorates into severe depressive episodes on top of it. Persistent depression disorder accounts for a significant proportion of depressive disorder, with a lifetime prevalence of 3% to 6% in Western countries [3]. However, persistent depressive disorder has two major features, first, the absence of clearly delineated episodes and, second, the long duration, which can occur below or above the specified critical point of 1 or 2 years [1]. It's possible that some individuals won't seek care until they've been struggling with symptoms of depression for decades,

not simply two years later. This article focuses on the etiology and treatment. The etiology will be discussed in two parts firstly genes and secondly environment. Treatment is based on medication and cognitive therapy to illustrate the most common forms of treatment

2. Etiology

There are a number of studies that have been written that describe what precisely causes depression. These publications clarify what causes depression. There is a biopsychosocial definition of depression that describes it as a complex illness condition that is produced by social and psychological elements [4]. This approach is commonly acknowledged by the medical community. Genes are the first factor to consider; they are passed down from parent to child in humans, and they are primarily responsible for the chemical components of depression in the brain. The second theory is that one's surroundings may bring on depression. This theory is probably held by the vast majority of people, who believe that it is the environmental factors that have the biggest impact. The influence that gender has on the disorder will be examined in the next paragraph. The therapy consists of two primary aspects, the first of which is medicine, and the second of which is cognitive treatment. Both of these parts are equally important. There has been little study done on the environmental components of the etiology of depression, therefore it is difficult to provide a complete explanation of the connection between depression and the environment. Additionally, the environmental factors do not include the environment of the family. It is envisaged that in the future there will be an increase in the number of longitudinal studies that are undertaken to demonstrate the effect of the home environment.

2.1. Physiology

Neurotransmitters are a topic that cannot be ignored in many mental illnesses, and usually the neurotransmitters in the brain of a person with a mental illness will be different from those of a normal person. The pathophysiology of persistent depression and depressive disorders remains a major area of research [5]. The brain's chemical state may be affected by a variety of factors, including the intricate interactions that take place between neurotransmitters and receptors. In most cases, serotonin is the neurotransmitter that is at issue and the one that is targeted by pharmaceutical intervention. Dopamine, epinephrine, norepinephrine, GABA, and glutamate are some examples of other neurotransmitters that have been found as influencing mood [4]. The frontal regions of the brain, and hippocampus show large to moderate volume reductions. Serotonin is a major factor in bodily functions such as mood and sleep. Serotonin in the brain regulates mood. It is often referred to as the body's natural "feel good" chemical. However, when a person suffers from depression, the secretion of serotonin is suppressed.

2.2. Genetic

There is much that remains to be determined about the influence of genetics on mental illness. but most researchers believe that genetics affects mental illness. Genetic inheritance is a very complex procedure. major depressive disorder is a common and moderately heritable disorder. Most psychological disorders result in overproduction or suppression of neurotransmitters. For example, 5-HTTLPR is a 5' proximal del-ins polymorphism associated with decreased transcriptional efficiency and function of 5-HTT, which in turn is associated with altered uptake of 5-hydroxytryptamine by the synaptic cleft [6]. It has been observed that promoter transcription levels are significantly lower in s-allele carriers of 5-HTTLPR than in L-allele carriers and result in altered 5-hydroxytryptamine uptake. As noted in several studies [6]. Transcriptional potency of 5-HTT interferes with basal regulation of mood, circadian cycles, sleep, motor function, sexual behavior, and appetite. The study of this gene polymorphism involved in some psychiatric diseases has not been

reported yet. There are nearly 20,000 nuclear genes have been identified, most of which function in neuronal regions (the brain). Some traits reflect many genetic and environmental factors. The responsibility of gene expression remains that, while there are genes, they don't always express themselves in the same way, due to the fact that the intricacy of this construct has significant repercussions for the field of research concerning mental diseases. Investigations of genetics using traditional methods are highly helpful, and the information obtained from these studies provides the current support for the idea that mental diseases have a hereditary foundation. Such investigations produce a baseline of genetic influences that distinguish genetic influences from those of the environment. However, there is a limit to what ordinary genetic studies can reveal [6].

2.3. Environment

Most of the effects of environment and gender on depression are on major depressive disorder, as mentioned above persistent depressive disorder and major depressive disorder have many similarities in etiology, perhaps this study can also give us some inspiration for persistent depressive disorder. There is research about work environmental factors [7]. This experiment looked for answers from 2,752 participants. The experiment was conducted from a variety of perspectives, including each participant's education, hours of work, personal income, satisfaction with the work environment, and family-work conflict. This is the first population-based longitudinal study [7] that combines assesses MDD using a structured diagnostic interview and three widely used occupational health models. According a large sample, they are able to study the connection that exists between the three models and the likelihood of men and women developing MDD. They discovered that multiple processes may be at play when job strain ratio, effort-reward imbalance, and work-family conflict increase the likelihood of major depressive disorder (MDD). The correlation between work strain ratio and major depressive disorder is not linear and varies depending on the person's gender. In a similar vein, the association between an effort-reward imbalance and the likelihood of major depressive disorder is not the same for men and women. A high job strain ratio, men are at high risk of MDD due to low job security and family work conflicts. Long working hours, such as 35 to 40 hours per week, effort-reward mismatch, job instability, and work-family conflict are the main causes of the higher risk of MDD in women [7]. In the workplace, high JSR and ERI are typical and may increase the risk of MDD. The processes, however, could be gender specific. Future study needed to confirm the gender-specific association between these work environment variables and MDD. Future research with large sample sizes should also look at how modifications to the workplace increase the risk of MDD. These might aid in the creation of preventative measures.

3. Treatment

3.1. Medication

In general, therapy and management of persistent depressive disorder and major depressive disorder are accomplished in a manner that is quite similar to one another [4]. Selective serotonin reuptake inhibitors (SSRIs) are often used as first-line treatments for depression because their specificity results in fewer drug interactions, they are safe in overdose and have favorable side effects. Medications known as serotonin-norepinephrine reuptake inhibitors (SNRIs) are also useful in the treatment of anxiety and depression [8]. They may be of particular benefit in cases of SSRI insensitivity as well as certain disorders associated with persistent pain. However, they are also often expensive as a result. Tricyclic antidepressants (TCAs) are older, inexpensive drugs that also act primarily by inhibiting the reuptake of 5-hydroxytryptamine and norepinephrine, are effective antidepressants, and are effective in treating chronic pain [5]. They work well because they also interact with many other receptors, but their tolerability and compliance can also limit them which

are their side effects. The drugs that have been used a lot for the patients who with atypical depression or that have failed to respond to other drug treatments are Monoamine oxidase inhibitors (MAOIs) [5]. In individuals diagnosed with atypical depression, response rates for MAOIs have been observed to range anywhere from 59% to 71%. MAOIs are also effective in PD, and it is possible that they are especially well adapted to treat depression in people who have this condition. Monoamine oxidase (MAO)-A and -B are enzymes that are responsible for breaking down monoamines such as 5-hydroxytryptamine, dopamine, and norepinephrine. These medications function by suppressing MAO-A and MAO-B. Ibuprofen and mirtazapine are two further examples of antidepressants [8]. In comparison to TCAs, these medications have a lower risk of adverse effects, with mirtazapine having an especially favorable safety profile. Bupropion has dopaminergic properties and a stimulant effect; It is used as a smoking cessation aid and without a few sexual side effects. Bupropion does not put people with epilepsy or bulimia at increased risk of seizures. Because there are not many drug interactions, mirtazapine is relatively easy to mix with other medications. Weight gain and drowsiness are two of the adverse effects that might occur as a result of blocking histamine H1 receptors [8]. The addition of lithium or thyroid hormones to antidepressant treatment, despite the fact that the majority of these investigations were carried out with tricyclic antidepressants and that very few of this research included contemporary antidepressants. In instances of antidepressant treatment resulting in just a partial or nonexistent improvement, various naturopathic and psychostimulant drugs have been suggested to have an augmentation function by a number of studies [8].

3.2. Cognitive Therapy

General terms for a range of different forms of interventions are cognitive therapy and cognitive-behavioral therapy, and this psychotherapy approach is difficult to find a simple definition to adequately describe [9]. The intervention is classified as a necessary criterion for "cognitive therapy", where the intervention makes an effort to connect ideas, emotions, and actions, and then relate them to symptoms of depression. Interventions that aim to detect and modify illogical thinking or behavior patterns, as well as relate such patterns to depressed symptoms, are considered to be effective [9]. It is the goal of interventions to educate patients on alternative modes of thought and behavior and to establish a connection between these modes of operation and depressed symptoms. Interventions are face-to-face and can be individual or small. provided that the co-intervention is analogous to cognitive therapy and that the intervention is given in the same manner to both the experimental group (cognitive therapy) and the control group.

The combination of antidepressant medication and psychotherapy to treat dysthymia has superiority [10]. particularly for those who have been depressed for an extended period of time It was determined to create the Cognitive Behavioral Analysis System of Psychotherapy for short [11]. This strategy makes use of an organized, guided "social problem-solving algorithm" to handle interpersonal obstacles, including how individuals establish cognitive and behavioral patterns, as well as how they manage issues pertaining to their relationships. In a similar vein, it has been shown that exercise may be an adjuvant therapy for depression; however, the benefits of exercise on dysthymia are not yet well understood [12]. People who adopt better habits of nutrition, physical exercise, relaxation/sleep, drug use, and social contact are considered to experience an improvement in their depression. This practice, known as lifestyle medicine, may be a kind of treatment for depression [1], health Professionals can let clients to consider make some changes in their practices in these areas. There is a considerable link between quality of life and suicide rates, with those who have a worse quality of life having greater rates of suicidal thoughts. Persistent depression is a prevalent mental health condition. about one-third of people with depression receive treatment [13]. After about two and a half years, when individuals suspected of having mental problems were re-interviewed, 57% of them did not meet the diagnostic criteria for a mental disease. As was to be predicted, there was a

large drop in the number of times that this recovered group participated in therapy. However, in the group of people who continued to be sick, there was only a little rise in the consumption of medicine, and there was no rise in the consumption of counseling. There is some evidence that interpersonal psychotherapy is the most successful kind of psychotherapy, whereas psychodynamic and non-directive counseling therapies may be less effective than interpersonal psychotherapy in terms of treating mental health issues. The fact that some of the underlying reasons or triggers of PDD are interpersonal in character may contribute, at least in part, to the effectiveness of interpersonal treatment. Long-term treatment, whether it be via the use of medicine, psychotherapy, or any mix of the two, is connected with better results [3]. Although there are medicinal therapies available for persistent depression, clinicians continue to be dissatisfied in clinical practice by the poor success rate of therapy for persistent depression and the high incidence of recurrence following treatment for persistent depression. First, individuals often seek therapy several years after the commencement of their condition due to their fear of being discriminated against. Second, unawareness; the majority of persons who have PDD believe that their pessimism and irritability are natural parts of their personality and thus cannot be treated for the condition. Third, the duration of treatment: because of the nature of persistent depression, even after receiving adequate treatment, some patients who seem to have been cured become inactive in the later stages of treatment, which can lead to a recurrence of the condition. This is since the treatment has been prolonged. Finally, resistance to therapy due to PDD, which causes patients to have negative attitudes that result in unfavorable treatment [3]. Some individuals could be unwilling to accept a diagnosis of depression, and as a result, they might not get any therapy for their condition. Some individuals can be apprehensive to start a certain therapy.

Some people refuse to use antidepressants due to concerns about "addiction," "needing a crutch," using "mind control medicines," or other factors; After taking antidepressants, some persons may be prone to mislabeling symptoms from before treatment as drug-related symptoms. Some patients could steer clear of psychotherapy because of concern that it would be intrusive, complicated, time-consuming, costly, or only address their past traumas as children. Patients who start therapy may get discouraged by unanticipated or unpleasant pharmaceutical side effects, delays in making enough progress, or trouble building a therapeutic relationship with a psychotherapist. Even if mental health treatments are accessible, patients may be discouraged from seeing one. Numerous studies [10] have shown that the combination of psychotherapy with the use of antidepressants results in higher response rates than pharmacotherapy alone. It is difficult to say whether the observed superiority of the combination treatment corresponds to the added benefit of psychotherapy or to a non-added phenomenon. However, the results suggest that adding psychotherapy can reduce non-response and help maintain patient therapy [10].

4. Conclusions

This article highlights the etiology and treatment. There are many causes that may lead to persistent depressive disorder and major depressive disorder, which can be broadly classified as physiological and environmental. Physiology can include many factors such as neurotransmitters, gender, and genetics. Research on neurotransmitters needs to go deeper, and studies on genetic effects on neurotransmitters are hard to find, so hopefully see more research on physiological aspects in the future. There are few experiments and studies on the effect of environment on persistent depression, so this paper uses the experiment of major depressive disorder to illustrate the effect of environment on depression. here are distinctions between major depressive disorder and persistent depressive disorder, despite the fact that their etiologies are extremely similar, and studies on persistent depression disorder are challenging since they take a long period. The precise and particular impacts of environment on chronic depression are an issue that is anticipated to be addressed in a study that will eventually be published. Because the therapy for major depressive disorder and persistent

depressive disorder is now essentially the same, it is utilized in this article. There are many different types of medications, but many of them have been eliminated because of side effects or other reasons. Many people with depression are unwilling to face it or do not pay enough attention to it, which can make it worse. The point of this article is to give people an understanding of major depression and persistent depression and why they have it and how to treat it, including prevention. Research on the etiologic of depression is limited to longitudinal studies that are difficult to conduct because of the amount of time required and the long-term cooperation of volunteers. Such experiments will certainly emerge in the future.

References

- [1] Melrose, S. (2019, August 7). *Persistent depressive disorder or dysthymia: An overview of assessment and treatment approaches*. Go to the cover page of Sherri Melrose Publications: A Virtual Memory Box. Retrieved September 21, 2022, from <https://sherrimelrosepublications.pressbooks.com/chapter/persistent-depressive-disorder-or-dysthymia-an-overview-of-assessment-and-treatment-approaches/>
- [2] Schramm, E., Klein, D. N., Elsaesser, M., Furukawa, T. A., & Domschke, K. (2020, August 20). *Review of dysthymia and persistent depressive disorder: History, correlates, and clinical implications*. *The Lancet Psychiatry*. Retrieved September 21, 2022, from <https://www.sciencedirect.com/science/article/abs/pii/S2215036620300997>
- [3] Lu, J. (2021, December 24). *A systematic review of the history, cause, and treatment of persistent depressive disorder*. *A Systematic Review of the History, Cause, and Treatment of Persistent Depressive Disorder | Atlantis Press*. Retrieved September 21, 2022, from <https://www.atlantis-press.com/proceedings/ichess-21/125966985>
- [4] GM;, P. R. K. R. (n.d.). *Persistent depressive disorder*. National Center for Biotechnology Information. Retrieved September 21, 2022, from <https://pubmed.ncbi.nlm.nih.gov/31082096/>
- [5] Define_me. (n.d.). Retrieved September 21, 2022, from [https://www.psych.theclinics.com/article/S0193-953X\(11\)00119-5/fulltext](https://www.psych.theclinics.com/article/S0193-953X(11)00119-5/fulltext)
- [6] V, R., & A, L. (2021, February 5). *Genetic variants associated with persistent depressive disorder*. *Mathews Journal of Psychiatry & Mental Health*. Retrieved September 21, 2022, from <https://www.mathewsopenaccess.com/full-text/genetic-variants-associated-with-persistent-depressive-disorder>
- [7] Wang, J. L., Patten, S. B., Currie, S., Sareen, J., & Schmitz, N. (2012, July 1). *Population-based longitudinal study on work environmental factors and the risk of major depressive disorder*. *OUP Academic*. Retrieved September 21, 2022, from <https://academic.oup.com/aje/article/176/1/52/132093>
- [8] Soleimani, L., Lapidus, K. A. B., & Iosifescu, D. V. (2011, February 1). *Diagnosis and treatment of major depressive disorder*. *Neurologic Clinics*. Retrieved October 11, 2022, from [https://www.neurologic.theclinics.com/article/S0733-8619\(10\)00137-4/fulltext#secd46782560e1011](https://www.neurologic.theclinics.com/article/S0733-8619(10)00137-4/fulltext#secd46782560e1011)
- [9] Jakobsen, J. C., Hansen, J. L., Storebø, O. J., Simonsen, E., & Gluud, C. (n.d.). *The effects of cognitive therapy versus 'no intervention' for major depressive disorder*. *PLOS ONE*. Retrieved October 11, 2022, from <https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0028299>
- [10] Sandro Pampallona, S. D. (2004, July 1). *Combined pharmacotherapy and psychological treatment for depression*. *Archives of General Psychiatry*. Retrieved October 19, 2022, from <https://jamanetwork.com/journals/jamapsychiatry/article-abstract/482031>
- [11] Serbanescu, I., Backenstrass, M., Drost, S., Weber, B., Walter, H., Klein, J. P., Zobel, I., Hautzinger, M., Meister, R., Härter, M., Schramm, E., & Schoepf, D. (1AD, January 1). *Impact of baseline characteristics on the effectiveness of disorder-specific cognitive behavioral analysis system of psychotherapy (CBASP) and supportive psychotherapy in outpatient treatment for persistent depressive disorder*. *Frontiers*. Retrieved September 21, 2022, from <https://www.frontiersin.org/articles/10.3389/fpsy.2020.607300/full>
- [12] *Cochrane Database of Systematic Reviews: All issues*. (n.d.). Retrieved September 21, 2022, from <https://www.cochranelibrary.com/cdsr/table-of-contents?volume=2021&issue=5>
- [13] M.D., A. S. Y., Search for more papers by this author, Ph.D., R. K., M.P.H., R. S., M.D., K. B. W., Dr. Young and Ms. Shoai are affiliated with the Mental Illness Research, & O'Loughlin, R. E. (2015, January 13). *Persistent depression and anxiety in the United States: Prevalence and quality of care*. *Psychiatric Services*. Retrieved September 21, 2022, from <https://ps.psychiatryonline.org/doi/full/10.1176/ps.2008.59.12.1391>